| |
| |
|
| Insider
Information: |
Link William J Phd |
| Relationship: |
|
| City: |
Santa Ana |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
836,870 |
|
|
Indirect Shares
|
8,818,270 |
|
|
| Direct
Value |
$5,736,432 |
|
|
|
Indirect Value
|
$45,508,938 |
|
|
| Total
Shares |
9,655,140 |
|
|
| Total
Value |
$51,245,370 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
2
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
1
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -26.5%
|
-8.2%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Edwards Lifesciences Corp |
EW |
Director |
2020-05-08 |
11,349 |
2020-05-08 |
10,772 |
Premium* |
|
|
Inogen Inc |
INGN |
Director, 10% Owner |
|
0 |
2014-02-20 |
3,695,816 |
Premium* |
|
|
Vivani Medical, Inc |
VANI |
Director |
2018-06-01 |
115,186 |
2017-06-01 |
4,492,975 |
Premium* |
|
|
Glaukos Corp |
GKOS |
Director |
2021-06-03 |
17,821 |
2021-06-03 |
40,479 |
Premium* |
|
|
Oyster Point Pharma, Inc. |
OYST |
Director |
2022-01-05 |
10,066 |
2022-01-05 |
447,088 |
Premium* |
|
|
Lensar, Inc. |
LNSR |
Director |
2023-05-25 |
521,267 |
|
0 |
Premium* |
|
|
Tarsus Pharmaceuticals, Inc. |
TARS |
Director |
2023-06-16 |
136,632 |
2023-05-11 |
109,892 |
Premium* |
|
|
Rxsight, Inc. |
RXST |
|
2024-02-01 |
24,549 |
2024-02-01 |
21,248 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RXST |
Rxsight, Inc. |
|
– • – |
2024-02-01 |
4 |
GD |
$0.00 |
$0 |
I/I |
3,000 |
21,248 |
0 |
- |
|
| RXST |
Rxsight, Inc. |
|
– • – |
2024-02-01 |
4 |
S |
$49.54 |
$1,403,120 |
I/I |
(28,250) |
24,248 |
0 |
% |
|
| RXST |
Rxsight, Inc. |
Director |
– • – |
2023-08-17 |
4 |
A |
$0.00 |
$0 |
I/I |
21,248 |
52,498 |
0 |
- |
|
| RXST |
Rxsight, Inc. |
Director |
– • – |
2023-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,610 |
24,549 |
0 |
- |
|
| RXST |
Rxsight, Inc. |
Director |
– • – |
2023-08-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(694,124) |
0 |
0 |
- |
|
| TARS |
Tarsus Pharmaceuticals, I... |
Director |
– • – |
2023-06-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,000 |
136,632 |
0 |
- |
|
| RXST |
Rxsight, Inc. |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,731 |
21,939 |
0 |
- |
|
| LNSR |
Lensar, Inc. |
Director |
– • – |
2023-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
9,288 |
521,267 |
0 |
- |
|
| RXST |
Rxsight, Inc. |
Director |
– • – |
2023-05-11 |
4 |
D |
$0.00 |
$0 |
I/I |
(258,390) |
0 |
0 |
- |
|
| RXST |
Rxsight, Inc. |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
I/I |
98,715 |
694,124 |
0 |
- |
|
| TARS |
Tarsus Pharmaceuticals, I... |
Director |
– • – |
2023-05-11 |
4 |
AS |
$0.00 |
$0 |
I/I |
(215,576) |
0 |
0 |
- |
|
| TARS |
Tarsus Pharmaceuticals, I... |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
I/I |
41,219 |
109,892 |
0 |
- |
|
| TARS |
Tarsus Pharmaceuticals, I... |
Director |
– • – |
2023-03-15 |
4 |
A |
$0.00 |
$0 |
I/I |
52,194 |
68,673 |
0 |
- |
|
| TARS |
Tarsus Pharmaceuticals, I... |
Director |
– • – |
2023-03-15 |
4 |
AS |
$0.00 |
$0 |
I/I |
(215,575) |
215,576 |
0 |
- |
|
| TARS |
Tarsus Pharmaceuticals, I... |
Director |
– • – |
2022-11-10 |
4 |
AS |
$0.00 |
$0 |
I/I |
(215,575) |
431,151 |
0 |
- |
|
| TARS |
Tarsus Pharmaceuticals, I... |
Director |
– • – |
2022-11-10 |
4 |
A |
$0.00 |
$0 |
I/I |
8,382 |
16,479 |
0 |
- |
|
| RXST |
Rxsight, Inc. |
Director |
– • – |
2022-11-09 |
4 |
D |
$0.00 |
$0 |
I/I |
(316,694) |
258,390 |
0 |
- |
|
| RXST |
Rxsight, Inc. |
Director |
– • – |
2022-11-09 |
4 |
A |
$0.00 |
$0 |
I/I |
107,236 |
595,409 |
0 |
- |
|
| TARS |
Tarsus Pharmaceuticals, I... |
Director |
– • – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
I/I |
3,749 |
8,097 |
0 |
- |
|
| TARS |
Tarsus Pharmaceuticals, I... |
Director |
– • – |
2022-08-15 |
4 |
AS |
$0.00 |
$0 |
I/I |
(215,575) |
646,726 |
0 |
- |
|
| RXST |
Rxsight, Inc. |
Director |
– • – |
2022-08-10 |
4 |
A |
$0.00 |
$0 |
I/I |
107,236 |
488,173 |
0 |
- |
|
| RXST |
Rxsight, Inc. |
Director |
– • – |
2022-08-10 |
4 |
D |
$0.00 |
$0 |
I/I |
(316,694) |
575,084 |
0 |
- |
|
| RXST |
Rxsight, Inc. |
Director |
– • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
10,349 |
47,458 |
0 |
- |
|
| LNSR |
Lensar, Inc. |
Director |
– • – |
2022-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,285 |
511,979 |
0 |
- |
|
| RXST |
Rxsight, Inc. |
Director |
– • – |
2022-05-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(375,000) |
1,266,778 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
